AKTOCYTE tablets – Revolutionizing Cancer Care + Infographic

ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 19 April. Click Here for more information.

ForumIAS Answer Writing Focus Group (AWFG) for Mains 2024 commencing from 24th June 2024. The Entrance Test for the program will be held on 28th April 2024 at 9 AM. To know more about the program visit: https://forumias.com/blog/awfg2024

Source– This post is based on the article “Breakthrough Nutraceutical ‘AKTOCYTE’ by the Department of Atomic Energy Set to Transform Cancer Care” published in “PIB” on 13th December 2023.

Why in the News?

AKTOCYTE tablets have been granted approval by the Food Safety and Standards Authority of India (FSSAI).

What are AKTOCYTE tablets?
AKTOCYTE

AKTOCYTE tablets
Source- PIB
SpecificationsDetails
What is it?Its a tablet used during cancer treatment to minimize the side effects of radiotherapy.
Developed byDepartment of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru
Characteristics1) Impressive Recovery in Pelvic Cancer: AKTOCYTE Tablets show promise in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine).
2) Versatile AKTOCYTE Tablets: Beyond a supplement, they serve as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, highlighting their diverse applications in cancer care.
3) Safe: AKTOCYTE has received approval from the FSSAI.
Market EntryAKTOCYTE Tablets, set to debut in January 2024, promise to revolutionize cancer treatment protocols.

What is FSSAI?

1) Food Safety and Standards Authority of India (FSSAI) is a statutory body established under the Food Safety and Standards Act, 2006 (FSS Act).

2) FSSAI is an autonomous body under the Ministry of Health & Family Welfare.

For more information on FSSAI Click Here to Read

UPSC Syllabus- Science & Technology

Print Friendly and PDF
Blog
Academy
Community